01 / DESIGN
What was studied?
A subgroup analysis used an existing blinded trial to examine people with HIV receiving integrase-inhibitor-based treatment.
02 / FINDINGS
What did the researchers report?
Among the reported participants, tesamorelin reduced visceral and hepatic fat measurements relative to placebo, with comparable reported adverse-event frequencies.
03 / LIMITS
How should it be interpreted?
The subgroup was small and derived from a parent study. It is not an independent replication or evidence for effects in people without HIV.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.